Ripretinib Used for Resectable Metastatic GIST After Failure of Imatinib Therapy

Ripretinib Used for Preoperative Treatment of Potentially Resectable Locally Advanced and Recurrent Metastatic GIST After Failure of Imatinib Therapy: An Exploratory Study

To explore the efficacy and safety of preoperative treatment of potentially resectable locally advanced or recurrent metastatic gastrointestinal stromal tumor (GIST) after failure of treatment.

Study Overview

• Status: Recruiting
• Conditions: Gastrointestinal Stromal Tumors
• Intervention / Treatment: Drug: Ripretinib treatment

Detailed Description

This study is a single-arm, single-center, exploratory study. A total of 20 patients were enrolled. The patient was orally administered with 150 mg of ripretinib daily. The study is expected to enroll the first patient in August 2021, last patient before March 30, 2023 and end the trial in November 2023. Subjects will receive up to 6 cycles of treatment before surgery, which will occur 1 week after the last dose of study drug. The subject requires discontinuation of study treatment or withdrawal from the study due to disease progression, intolerable toxicity, or Investigator's judgment.

The study will be divided into 3 periods: screening period, treatment period (visit period) and follow-up period. All subjects in the study were required to meet all inclusion criteria and exclusion criteria.

In this study, the screening period did not exceed 28 days, and eligible subjects who completed the screening tests and assessments entered the treatment period for study treatment and visits as specified in the protocol. Thereafter, participants entered the follow-up period. The safety follow-up period begins with 30 days of study treatment until 90 days after dosing, and subjects should receive telephone assessments every 30 days. After the safety follow-up period, subjects entered the survival follow-up period. Survival follow-up will be performed every 3 months until 1 year after treatment. Survival information and subsequent treatment information can be collected by effective means such as telephone follow-up. For subjects without radiographic evidence of disease progression, radiographic assessments should continue to be performed at the frequency of efficacy evaluations specified for this study.

• Study Type: Interventional
• Enrollment (Anticipated): 20
• Phase: Not Applicable

Contacts and Locations

Study Locations

• China
  • Shanghai
    • Shanghai, Shanghai, China, 200127
      • Recruiting
      • Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 75 years (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

Patients must meet all of the following inclusion criteria to be enrolled in the study:

1. Patients voluntarily, and signed a written informed consent, good compliance with follow-up;
2. 18 years ≤ age < 75 years, male or female;
3. Histopathological examination confirmed the diagnosis of gastrointestinal stromal tumors, and immunohistochemical detection of CD117 and/or DOG-1 positive;
4. According to the modified RECISTv1.1-GIST-specific (hereinafter referred to as"mRECIST") criteria, the subject has at least one measurable lesion (the long diameter of non-lymph node lesions is ≥ 1.0 cm or ≥ 2 times the scanning slice thickness); the lesions with definite progression after local treatment can also be considered as measurable lesions; the imaging results must be obtained within 21 days before the first dose;

5. Potentially resectable locally advanced or recurrent metastatic gastrointestinal stromal tumors who have failed imatinib treatment:

   • The number of evaluable lesions is ≤ 5 as judged by CT/MRI;

   • The resection is considered to have significant risks by MDT assessment (meeting any of the following):

     1. The maximum diameter of a single lesion is ≥ 10 cm;
     2. Organ function damage surgery is required (gastrectomy, total gastrectomy, hepatectomy residual liver body ≤ 50% of the normal liver volume);
     3. Multiple organ resection surgery is required (partial gastrectomy combined with pancreatectomy/splenectomy, pancreaticoduodenectomy and abdominoperineal resection);
6. The ECOG physical status score of patients is 0-2;

7. Good organ function and bone marrow reserve, including:

   • Neutrophil count ≥ 1.5 × 109/L
   • Hemoglobin ≥ 90 g/L
   • Platelets ≥ 100 × 109/L
   • Total bilirubin ≤ 1.5 × upper limit of normal (ULN)
   • AST and ALT ≤ 3 × ULN, and ≤ 5 × ULN in the presence of liver metastases
   • Serum creatinine ≤ 1.5 × ULN or creatinine clearance ≥ 50 mL/min (calculated according to Cockcroft-Gault formula)
   • Prothrombin time (PT), international normalized ratio (INR) and partial thromboplastin time ≤ 1.5 × ULN.
   • QTc ≤ 450 ms (male), 470 (female): LVEF ≥ 50%
8. Non-surgically sterilized or female patients of childbearing age need to use a medically recognized contraceptive (such as intrauterine device, contraceptives or condoms) during study treatment and within 90 days after the end of study treatment; non-surgically sterilized female patients of childbearing age need to confirm that they are not pregnant; and must be non-lactating; for male patients with partners of childbearing age, effective regimen contraception should be used during study treatment and within 90 days after the end of study treatment.

Exclusion Criteria:

Patients with any of the following will not be enrolled in the study:

1. Patients with other serious complications who cannot tolerate surgery: such as severe cardiopulmonary disease, heart function below clinical class 2, pulmonary infection, moderate to severe COPD, chronic bronchitis, severe diabetes and/or renal insufficiency, severe hepatitis and/or Child-pugh class C or B whose symptoms are significantly difficult to correct, severe malnutrition, etc.;
2. Occurrence of bleeding, perforation, obstruction and other disease-related complications, requiring emergency surgery;
3. Patients with severe mental illness;
4. The patient has participated in or is participating in other clinical studies , or is taking other TKI agents; has any clinically significant concurrent medical condition such as uncontrolled pulmonary disease, active infection, or any other condition that, in the opinion of the investigator, may affect patient compliance, interfere with interpretation of study results, or expose the patient to safety risks.
5. Active viral infections such as human immunodeficiency virus, hepatitis B, and hepatitis C
6. Pregnant or lactating female patients or patients expecting to become pregnant during study treatment
7. Known hypersensitivity to any component of the study drug.

8. Gastrointestinal abnormalities, including but not limited to:

   • Inability to swallow study drug
   • Malabsorption syndrome
   • Need for intravenous nutrition
9. Any active bleeding, excluding hemorrhoids or gingival bleeding. Has any clinically significant concurrent medical condition, such as uncontrolled pulmonary disease, active infection, or any other condition that, in the opinion of the investigator, may affect patient compliance, interfere with interpretation of study results, or expose the patient to safety risks.
10. The investigator considers that there are other factors that may affect the study results or cause the study to be terminated, such as alcoholism, drug abuse, other serious diseases (including mental illness) requiring concomitant treatment, severe laboratory abnormalities, with family or social factors that may affect the safety of patients.
11. Other patients who may affect the conduct of the clinical study in the judgment of the investigator, may be unable to comply with the agreement or unable to cooperate, patients with study risks.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: NA
• Interventional Model: SINGLE_GROUP
• Masking: NONE

Number of Arms

1

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

EXPERIMENTAL: Ripretinib treatment group

Drug: Ripretinib treatment; Ripretinib: 4-week (28-day) cycle of oral administration of 150 mg q.d. For patients who completed up to 6 consecutive treatment cycles in a the clinical investigator decided whether to perform the operation or not, the specific time and other matters. The above medications can be adjusted according to the adverse reactions of subjects according to the protocol at the investigator's discretion. Subjects will continue treatment until disease progression, intolerable toxicity, withdrawal of informed consent, or discontinuation of treatment as judged by the investigator, and the investigator will decide whether to perform early surgery or subsequent treatment regimen.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
No Evidence of Disease Rate (NED Rate)	The primary study endpoint is to investigate the disease-free status rate of ripretinib for the preoperative treatment of potentially resectable locally advanced or recurrent metastatic GIST (NED Rate defined as patients who achieve R0 resection or complete response or macroscopic complete ablation of all known tumor lesions based on imaging assessment, with known tumor lesions assessed by CT or MRI at baseline and within 14 days after surgery, respectively).	baseline
No Evidence of Disease Rate (NED Rate)	The primary study endpoint is to investigate the disease-free status rate of ripretinib for the preoperative treatment of potentially resectable locally advanced or recurrent metastatic GIST (NED Rate defined as patients who achieve R0 resection or complete response or macroscopic complete ablation of all known tumor lesions based on imaging assessment, with known tumor lesions assessed by CT or MRI at baseline and within 14 days after surgery, respectively).	within 14 days after surgery

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
R0/R1 resection rate	R0 is the proportion of patients with no microscopic residual after resection/R1 is the proportion of patients with microscopic residual.	1 days after surgery
Surgery rate	The proportion of patients who can undergo surgery.	up to 6 months
Objective response rate (ORR)	The proportion of patients who achieve complete response and partial response.	up to 24 months

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Recurrence-free survival (RFS)	The recurrence-free survival (RFS, defined as the time from initial surgery to the earliest evidence of recurrence) of potentially resectable locally advanced or recurrent metastatic GIST treated with preoperative therapy failure.	until the date of first documented progression, assessed up to 24 months
Overall survival (OS)	Overall survival (OS, defined as the time from randomization to death from any cause)	until the date of death from any cause, assessed up to 24 months

Collaborators and Investigators

• Sponsor: RenJi Hospital

Study record dates

Study Major Dates

• Study Start (ACTUAL): August 1, 2021
• Primary Completion (ANTICIPATED): November 30, 2023
• Study Completion (ANTICIPATED): November 30, 2023

Study Registration Dates

• First Submitted: September 15, 2021
• First Submitted That Met QC Criteria: November 12, 2021
• First Posted (ACTUAL): November 24, 2021

Study Record Updates

• Last Update Posted (ACTUAL): November 24, 2021
• Last Update Submitted That Met QC Criteria: November 12, 2021
• Last Verified: November 1, 2021

More Information

Terms related to this study

• Keywords: Imatinib; Gastrointestinal Stromal Tumors; Ripretinib
• Additional Relevant MeSH Terms: Digestive System Diseases; Neoplasms, Connective and Soft Tissue; Neoplasms by Histologic Type; Neoplasms; Gastrointestinal Neoplasms; Digestive System Neoplasms; Gastrointestinal Diseases; Neoplasms, Connective Tissue; Gastrointestinal Stromal Tumors
• Other Study ID Numbers: Ripretinib for GIST

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No